Entero Healthcare Solutions Ltd

Entero Healthcare Solutions Limited announced the allotment of 43,155 equity shares of Rs 10 each to eligible employees upon the exercise of vested options under the Entero Employee Stock Option Plan 2023, according to a regulatory filing on October 12, 2026. The shares were allotted at an exercise price of Rs 804 for 19,155 shares and Rs 1,124 for 24,000 shares, resulting in a total issued share capital of Rs 43,56,62,270.

Entero Healthcare Solutions Limited (BSE: 544122, NSE: ENTERO) will close its trading window for securities transactions for designated persons and their immediate relatives starting October 1, 2026, and continuing for 48 hours after the declaration of the company’s unaudited financial results for the quarter ended September 30, 2026, as per the company’s Code of Fair Disclosure.

Entero Healthcare Solutions Limited informed the BSE and NSE that the tenure of Rajesh Shashikant Dalal (DIN: 03504969) as Non-Executive Independent Director concluded on August 24, 2026, resulting in his resignation as Chairperson of the Nomination and Remuneration Committee, Stakeholders Relationship Committee, and member of the Audit Committee.

Entero Healthcare Solutions Ltd share price slipped 1.30% to Rs 1241.55. The Company's net profit improved by 15.33% to Rs 52.05 crore, while revenue from operations improved marginally 1.60% to Rs 1940.5 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmacy Retail industry group stocks on BSE stood at Rs 15833.4 crore, rising 1.21%. It has slipped by 1.34% over last one week and dropped by 13.48% in last one month while the market capitalization of Entero Healthcare Solutions Ltd has softened by 0.25% and 1.40% in the same period respectively. Profit before tax (PBT) of Entero Healthcare Solutions Ltd stood at Rs 67.12 crore in Q2 FY26, surging by 84.60% year-on-year, and jumping 15.82% quarter-on-quarter. EBITDA came in at Rs 94 crore, expanding by 112.45% YoY and improving 14.58% sequentially. Total expenses inched up 0.93% to Rs 1855.81 crore in Q2FY26 over Q2FY25. During the quarter, employee benefits expense was at Rs 69.42 crore, rising by 7.20% YoY. For the TTM ended FY26, revenue from operations soared by 29.35% to Rs 6591.21 crore, while net profit jumped 35.75% to Rs 145.84 crore, compared to previous TTM. EBITDA surged by 14364% to Rs 246.71 crore, and PBT witnessed a strong rise of 29.26% to Rs 179.34 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 96.2 crore in FY26, as against Rs 76.86 crore in FY25. Entero Healthcare Solutions Ltd declined by 2.21% in last one year, performing in line with the benchmark BSE Sensex which has slipped by 1.97% during the same period.

Entero Healthcare Solutions Limited informed the Bombay Stock Exchange and National Stock Exchange that its step-down subsidiary, Qurovia Lifesciences Private Limited, was incorporated in India on July 25, 2026, with its registered office in Bangalore, Karnataka. Qurovia, which will focus on the wholesale and retail distribution of pharmaceuticals and healthcare products, was incorporated with an authorized share capital of Rs 1,50,00,000 and R S M Pharma Private Limited, a wholly owned subsidiary of Entero Healthcare Solutions Limited, subscribed to 10,000 equity shares, aggregating to Rs 1,00,000.

Entero Healthcare Solutions will hold a meeting of the Board of Directors of the Company on 7 August 2026.

Entero Healthcare Solutions announced that the 8th Annual General Meeting(AGM) of the company will be held on 19 August 2026.

Net profit of Entero Healthcare Solutions rose 9.03% to Rs 28.01 crore in the quarter ended March 2026 as against Rs 25.69 crore during the previous quarter ended March 2025. Sales rose 42.63% to Rs 1909.93 crore in the quarter ended March 2026 as against Rs 1339.06 crore during the previous quarter ended March 2025. For the full year,net profit rose 21.32% to Rs 115.04 crore in the year ended March 2026 as against Rs 94.82 crore during the previous year ended March 2025. Sales rose 29.35% to Rs 6591.21 crore in the year ended March 2026 as against Rs 5095.78 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales1909.931339.06 43 6591.215095.78 29 OPM %4.503.65 -4.033.37 - PBDT72.7445.72 59 230.81169.43 36 PBT57.9537.23 56 187.52138.74 35 NP28.0125.69 9 115.0494.82 21 Powered by Capital Market - Live

Entero Healthcare Solutions will hold a meeting of the Board of Directors of the Company on 25 May 2026.

Net profit of Entero Healthcare Solutions rose 8.61% to Rs 27.63 crore in the quarter ended December 2025 as against Rs 25.44 crore during the previous quarter ended December 2024. Sales rose 25.57% to Rs 1706.52 crore in the quarter ended December 2025 as against Rs 1359.00 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales1706.521359.00 26 OPM %3.973.68 - PBDT58.3847.54 23 PBT48.5839.44 23 NP27.6325.44 9 Powered by Capital Market - Live